How is CSI Innovative Drug Industry Index likely to move over the next seven days, and what position bias is appropriate?

The CSI Innovative Drug Industry Index is expected to experience upward momentum over the next seven days, driven by positive sector developments and favorable market conditions. The high-probability scenario suggests a significant policy announcement or breakthrough in drug development, which would boost investor confidence and drive index gains. The latest 24 hours have not produced any marginal changes that weaken this outlook, reinforcing the expectation of a positive trend.

The structural regime for CSI Innovative Drug Industry (931152) is a high-beta uptrend that has been digesting since early September. Verified daily bars show the index at 1910.01 on 2026-09-01, an intramonth high of 1926.41 on 09-04, a post-NRDL-negotiation flush to 1794.54 on 09-11, and a recovery to a 1880.55 close on 09-18 (the launch snapshot of 1880.5477 is that close, so scale is consistent). Persistent drivers are genuinely strong: 2026 out-licensing has passed USD 120bn (+36% y/y, upfronts >USD 10bn), H1 fundamentals were strong across large caps and CXO, PE-TTM was ~41.4x on 09-14 near a one-year low percentile, and on 2026-09-18 ten ministries led by MIIT issued the Pharmaceutical Industry 15th Five-Year Plan targeting >=20% average annual growth in innovative-drug industry scale and >=25% global first-in-class share by 2030. The dominant unresolved tension is whether that policy and BD tailwind can produce a directional move during a week that has no scheduled sector catalyst: the NRDL negotiation concluded 09-05 to 09-09 with results not published until November, WCLC already ran 09-12 to 09-15, and ESMO is not until 10-23 to 10-27. The window is structurally compressed - A-share cash markets are closed 09-25 to 09-27 for Mid-Autumn and reopen 09-28, so only about five sessions exist, with the 09-28 session sandwiched between that holiday and the 10-01 to 10-07 National Day break. Galaxy Securities explicitly framed the coming week as cross-holiday risk premium plus quarter-end institutional assessment producing continued chop and rotation. Two external frictions cap the upside tail: the Fed hiked 25bp to 3.75-4.00% on 09-16 with most officials projecting another hike, and the US 100% Section 232 tariff on patented pharmaceuticals and inputs becomes fully effective 09-29 for all remaining manufacturers with exemption guidance still lacking as of 09-14 - a headline risk for the index's heavy CXO and API constituents even though services and generics are largely insulated. In the latest 24 hours (09-19 to 09-20, cash market closed) there was no verified sector-specific marginal change: the 09-20 LPR fixing was unchanged for a sixteenth month (1Y 3.00%, 5Y+ 3.50%), and sell-side weeklies dated 09-20 were constructive but not new information. Mainline plus a neutral marginal check therefore points to a range-bound, rotation-driven week rather than a decisive >1.5% move in either direction, so I favor a neutral position bias.

The CSI Innovative Drug Industry Index (931152) is in a fresh policy-driven bullish regime following the September 18, 2026 joint release of the 'Medical Industry Development 15th Five-Year Plan' by ten ministries, which sets ambitious 2030 targets (scale-above pharma revenue over 3.5 trillion yuan, first-in-class innovative drugs above 25% of the global share, and innovative-drug compound growth above 20%). Persistent drivers are supportive: cumulative innovative-drug out-licensing has surpassed $120 billion, 59 innovative drugs were approved year-to-date as of mid-September, and ADC/IO clinical progress continues. The latest 24 hours (September 20) marginally strengthened the mainline—the NMPA pledged front-loaded guidance for novel-target, novel-mechanism innovative drugs, and broker weekly reports stayed bullish on the AI4S and 15th Five-Year Plan themes—with no verified reversal catalyst. The dominant unresolved tension is whether policy momentum and fund rotation can overcome pre-Mid-Autumn/National Day profit-taking and thinner holiday liquidity. Base case: catalyst digestion and persistent fund rotation push the seven-day open-to-close return above +1.50%, favoring a LONG bias.

The CSI Innovative Drug Industry Index (931152), starting from the launch snapshot baseline of 1880.5477, enters the September 21–28, 2026 forecast window with strong structural policy support and multi-day sector re-rating momentum. On September 18, 2026, ten Chinese central government departments released the landmark '15th Five-Year Plan for the Development of the Pharmaceutical Industry,' targeting over 20% annual growth for the innovative drug sector, a 25%+ global share of First-In-Class (FIC) drugs, and R&D investment intensity above 10% for listed biopharma. Combined with YTD 2026 outbound BD licensing deals exceeding $120 billion and a favorable global monetary easing environment, this top-tier policy catalyst is expected to drive sustained institutional capital inflows into index constituents, yielding a seven-day return above +1.50% from the 1880.5477 baseline.